Goingtomeet.com Press

Exploring the Potential Solar Energy Market in China and Upgrading Production Technology

CHANGZHOU, CHINA, 24-25 MARCH 2011 – China is now the world’s largest solar cell manufacturer with an annual output of 4,382 MW and the number is still increasing. The current yearly output of solar cells in Jiangsu Province accounts for 65% of the national output and 25% of global output.

Supported by Changzhou People’s Municipal Government and UNIDO ITPO-CHINA, the 3rd China Solar Energy Technology and Investment Congress organized by the Administrative Committee of Changzhou National High-Tech District and Noppen took place on 24-25 March 2011 in Changzhou. With over 150 attendees the congress brought together senior government officials, leading solar cell manufacturers and equipment suppliers from all over the world to discuss the latest industrial policies, China’s major solar projects progress, and advanced technology solutions and equipment selection.

Meeting between HAN Jiuyun, the Vice Mayor of Changzhou People’s Municipal Government and Dr. Mohan Narayanan, Vice President, Hanwha SolarOne Ltd

On day one morning, before the conference began, a meeting was held with HAN Jiuyun, the Vice Mayor of Changzhou People’s Municipal Government. He made a speech introducing the solar industry in Changzhou which was followed by selected attending delegates one by one introducing their companies. Meeting attendees included XUE Jiannan, Standing Committee, Changzhou National High-Tech District; ZHAO Hao, Director, Photovoltaic Industry Park, Changzhou New District Administration Office; QIU Dimin, Director of Technical Committee, Trina Solar Limited; JIANG Leiyan, Deputy Director, Changzhou National High-Tech District Business Council; and representatives from Hanwha SolarOne Ltd, Krempel Gmbh, TÜV Rheinland Co Ltd, etc. Following the meeting HAN Jiuyun gave a welcome speech opening the session; and DAI Yuan, Secretary of the Party Working Committee of Changzhou National Hi-tech District presented an overview of the solar industry and its investment environment in Changzhou. Currently, Changzhou National Hi-tech District is one of the most competitive development zones in east China. “The event is of high standard and provided rewarding results” Roger Shanghai Co Ltd

Key speakers at the event included Dr. REN Dongming, Director, Center for Renewable Energy Development, Energy Research Institute, NDRC who discussed the implementation of the latest government incentive policies and the development strategy for China’s solar industry. It was a very valued opportunity for our delegates to talk with the NDRC directly. Many questions were asked regarding the future of industrial distribution. Dr. YU Pingrong, Director, Solar Energy Center at Beijing University was Chairman of the conference. In addition to his speech on international industrial chain integration, Dr. Yu gave great remarks on each presentation and asked some challenging questions to aid the delegates in better understand the topics presented. ZHANG Wen, CEO and CTO of Dongfang Electric (Yixing) Magi Solar Power Technology Co Ltd introduced Magi Solar’s cost effective Athena I project. Efficiency levels are above 18.5% in mass production, a number which is leading in the current solar cell manufacturing industry. “Great sessions, very good one-to-one meetings!” Chroma Ate Inc. Notable speakers also included Dr. LUO Xiang National Program Director UNIDO ITPO-CHINA, who talked about issues related to the outsourcing industry chain. Dr. Luo’s presentation analyzed the current China solar industry from an investor’s viewpoint and provided the local investors with some new business model ideas. Currently UNIDO is investing heavily in China’s solar industry. Dr. Luo also presented a case study of the Changzhou Model, concluding that it is the most effective one as it puts emphases on the Brand + Capital + Industry chain. “The event was well organized and the topic areas covered by experts reasonable” State Grid Electric Power Research Institute

Industry leaders introduced their most up-to-date technology and product information. LI Zhanrong, Senior Advisor, Sichuan Xinguang Silicon-Tech Co Ltd compared different ways of producing polysilicon materials focusing on efficiency and raw materials consumption. Mr. Li has over 40 years work experience in semiconductor polysilicon materials’ research and development. Guy Rong, President and CEO, Suntrix Company Limited introduced SCPV technology which is the latest generation of solar PV technology. The SCPV developed by Suntrix is in the mass production stage with efficiency up to 25%. Dr. Ihor Melnyk fromCentrotherm Photovoltaics AG illustrated the latest developments in the crystalline silicon based photovoltaic technology manufacturing process, and from PICOSUN OY, Dr. LI Wei-min discussed atomic layer deposition technology for photovoltaic industrial applications. The new ALD technology can be used in thin-film solar cell manufacturing. Delegates showed great interest in this new technology and asked a lot of questions about the practice during the Q&A session. “Excellent, valuable and very profitable!” CECEP Solar Energy Technology Co Ltd

Prominent speakers also included Christian Dreier, Vice General Manager, TÜV Rheinland (Shanghai) Co Ltd which offers testing services to the solar industry. He discussed long-term outdoor exposure testing in different environments. Dr. Ray Lian of Solarbuzz showcased the latest industry data and forecasted the global PV market trends for 2011; and from Krempel Gmbh, Karlheinz Brust discussed guidelines for the successful selection of material components for PV modules, which can directly affect the performance of solar cells/modules both in efficiency and safety. Speakers also came from Ministry of Industry and Information Technology, Intertek Testing Services Limited, Hanwha SolarOne Ltd, New Energy Institute of DEC, Feng Neng Sgurr (Beijing) Renewable Energy Technology Co Ltd and Jetion Solar (China) Co Ltd.“Professional arrangement, excellent staff and very good translators” Sandvik Thermal Process Inc.

The event concluded on day three with a site tour to Trina Photovoltaic Industrial Park attended by some of Trina Solar’s senior leaders and also a visit to Changzhou National Hi-tech District. Trina currently has the largest vertically integrated PV chain in the world, from the production of ingots, wafers and cells to the assembly of high quality modules. “Thanks to the staff of Noppen. The organization was very good” Krempel Group. Noppen would like to express special thanks to the 3rd China Solar Energy Technology and Investment Congress sponsors; Krempel Group, Honoprof/Picosun, Intertek, Chroma, G-Crystal, Roger Shanghai, TÜV Rheinland, Yukun New Energy, LAND, BIG in our mind, ABB, GCL, Mitsun Chemicals Group, Bender, and Linde for their great contribution to the event. “The content was well-rounded and the event professional, really top notch!” China Power Investment Jiangsu Branch.

About Noppen

Noppen (Shanghai) Co., Ltd. has delivered exceptional events, assisted new market entries and established government relations since 1998. Our top-level business connections paired with our close relations to the many levels of government have given Noppen an edge on the marketplace our competitors just can’t match. With offices in China, India and Belgium, Noppen offers reputable, reliable service and a large range of deliverables to help your company successfully meet its goals.

Contact:

Christian Haller from MPR Product Development, a solution provider at the marcus evans Medical Device R&D Summit 2010, shares his thoughts on the most effective product development planning strategies.

Interview with: Christian Haller, Director MPR Product Development

Las Vegas, NV, July 2, 2010 – FOR IMMEDIATE RELEASE

Medical device Research and Development (R&D) directors very often come up with brilliant product ideas but do not necessarily plan the development process properly, according to Christian Haller, Director MPR Product Development. They end up spending substantially more time and money developing a product than they really need to. A solution provider at the marcus evans Medical Device R&D Summit 2010 taking place in June 20-22, Haller discusses best practices for product development and risk management.

What long-term strategies and best practices would you recommend?

Christian Haller: One of our primary approaches is to manage risks; not only technical risks but product and development risks, such as marketing, reimbursement, and regulatory approval. In our experience, many companies do not put sufficient effort upfront into planning out a detailed vision of what the product is, how it is going to be used and paid for, the business case of the product from the buyer’s point of view, and the user experience. While mostly everyone gets around to these activities, much time and effort can be saved by spending more time up front on these issues.

Medical device R&D directors should take more time planning, talking to potential users to find out what they really want from the product, and identifying how the product fits into the business model, not only as a manufacturer but how it fits into the consumers’ business model. They need to focus on the final outcome as early on as possible. This will mean fewer changes in the development process. Very often, people come up with an initial idea but do not think through all of these issues and they have to continually redefine the image of the product. They spend more time re-developing the product and as a result, substantially more money than they really need to.

These strategies also help in decreasing the time to market. We have reduced our average time of filing very complex devices to a year or just under. Compared to industry averages, we are proud of this metric. Of course, you cannot guarantee how long the US Food and Drug Administration (FDA) will take to approve a product, but planning upfront and a proactive approach with the FDA helps speed things up.

What challenges are medical device R&D directors in North America facing?

Christian Haller: The market is focused on coming up with new products with fewer resources. Many companies are cutting R&D budgets ahead of the taxes on medical devices, which will be imposed by the Health Care Reform Bill. People will have to keep doing more with less, in addition to having to come up with products that work better in order to be approved for use by the Bill.

There are also significant modifications to the FDA rules which we are not used to; there are many unknowns in that regard. From our experience, it is important to take a cooperative and proactive approach with regulators. R&D directors should spend a lot of time on due diligence and determining the best regulatory strategies, going to the FDA with their plans, defining their own recommended regulatory path and working to build consensus upfront. You have to be your own advocate with the FDA. Talk early and talk often, is what we tell to our clients.

How can the product lifecycle be extended?

Christian Haller: In the effort to get to the market quicker, we advise clients not to add too many features that are not absolutely essential. We have found that one of the best ways to extend the lifecycle of a product is to define the architecture of the device, so that additional features and applications can be added cost effectively later on. By defining the architecture appropriately, you enable the ability to refresh the product at a later stage.

When outsourcing parts of the R&D process, how can manufacturers ensure everything is in sync?

Christian Haller: Firstly, they need a detailed written plan from all solution providers that covers the entire development process. When we start a project, we give the client a very detailed plan covering all the stages of the project, all the deliverables and activities defined, with a detailed listing of what will and will not be included. It is important to communicate that effectively. Everything should be written down, from beginning to end. The two parties have to reach complete agreement on the plan and the review process before starting.

Secondly, the parties have to establish regular scheduled meetings, perhaps once a week either in person or via teleconference, to walk through the status of the job.

Thirdly, it is necessary to have a team at the outsourced end that is dedicated, and a project manager who is constantly in contact with the client, who will oversee the project from beginning to end. The team at the outsourced company should be an extension of the manufacturer’s own development team.

Lastly, the way we see it, it is more efficient to have third party suppliers who can do the entire job. One could hire a software company, an electronics company, and a mechanical design company, but that generally means getting all those different outsourced resources working together harmoniously, often a full time job. Going to a company with a proven track record that is able to do the entire job is key. People will be more motivated to cooperate with each when there are fewer companies involved.

Contact: Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division

About the Medical Device R&D Summit 2010

This unique forum will take place at the Red Rock Casino Resort & Spa, Las Vegas, Nevada, June 20-22, 2010. Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The summit includes presentations on emerging technologies, speeding product development and addressing the challenges of outsourcing.

For more information please send an email to Jana Urbanovska at news@marcusevanscy.com or visit the event website at www.medicalrdsummit.com/media_GTM_ch

Please note that the summit is a closed business event and the number of participants strictly limited.

About marcus evans Summits

marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings. For more information, please visit www.marcusevans.com

All rights reserved. The above content may be republished or reproduced kindly inform us by sending an email to news@marcusevanscy.com

href=”http://www.goingtomeet.com/conventions/details/54730″>Phase IV clinical trials are the fastest growing areas of clinical research. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which proves efficacy, safety and quality. Furthermore, a key driver is the demands of health technology assessors and payers and their need for evidence-based economic data, again over the long-term. However, as post-marketing studies tend to be more commercial in nature, successfully planning and implementing them can be a major challenge, especially in terms of motivating investigators and recruiting patients who may already have access to the latest medications.

This event will be looking moving towards „best-practice“approaches to designing and implementing post-marketing studies. Essential topics to be discussed will include:

* Study design considerations and implications
* Comparative studies
* Balancing the complex requirements of key stakeholders: marketing, clinical, regulatory, safety, KOLs and investigators
* Overcoming patient recruitment and retention challenges, when the product is commercially available
* Motivating academically –focused investigators for commercially-focused studies
* Finding and performance managing the right CRO
* Leveraging phase IV clinical research to maximise product life cycles
* Best practice approaches in phase IV clinical operations and implementation
* Outsourcing phase IV & observational studies

Why attend:

* Gain access to the latest methodologies and real-life cases in the field
* Explore how market leaders are improving data accuracy
* Balancing conflicting scientific, regulatory & marketing needs
* Learn more about comparative studies and their value for drug safety
* Understand how key figures are affecting future trends and standards
* Meet ethics committees to retrieve the full regulatory / ethical picture
* Find out how phase IV studies & observational research are being outsourced and how industry players are selecting the right partners

Who will benefit:

Pharmaceutical & biotech companies

Vice Presidents, Directors & Managers of: Medical Affairs, Epidemiology, Clinical Development & Operations, Drug Safety, Pharmacovigilance, Data Management, Regulatory Affairs, Clinical Outsourcing

Solution providers

CROs, EDC & Data Management, Clinical Software, Market Access & Health Outcomes Consultancies

Academics & doctors
Epidemiology, Principle Investigators, Primary Care

Government
Ministries of Health, Regulatory & Health Technology Assessment Agencies

To request the full agenda please follow the link:

https://www.nextlevelpharma.com/events/request_agenda/best_practice_in_phase_iv_clinical_observational_research

For Booking Information:

Tel: +421 232 660 382

Fax: +421 232 660 397
Email: erika@nextlevelpharma.com